

RESEARCH ARTICLE

Open Access

Evaluation of the *IL2/IL21*, *IL2RA* and *IL2RB* genetic variants influence on the endogenous non-anterior uveitis genetic predisposition

María Carmen Cénit^{1*}, Ana Márquez^{1†}, Miguel Cordero-Coma², Alejandro Fonollosa³, Alfredo Adán⁴, Agustín Martínez-Berriotxo³, Victor Llorenç⁴, David Díaz Valle⁵, Ricardo Blanco⁶, Joaquín Cañal⁷, Manuel Díaz-Llopis⁸, José Luis García Serrano⁹, Enrique de Ramón¹⁰, María José del Río¹¹, Marina Begoña Gorroño- Echebarría¹², José Manuel Martín-Villa¹³, Norberto Ortego-Centeno¹⁴ and Javier Martín¹

Abstract

Background: Recently, different genetic variants located within the *IL2/IL21* genetic region as well as within both *IL2RA* and *IL2RB* loci have been associated to multiple autoimmune disorders. We aimed to investigate for the first time the potential influence of the *IL2/IL21*, *IL2RA* and *IL2RB* most associated polymorphisms with autoimmunity on the endogenous non-anterior uveitis genetic predisposition.

Methods: A total of 196 patients with endogenous non-anterior uveitis and 760 healthy controls, all of them from Caucasian population, were included in the current study. The *IL2/IL21* (rs2069762, rs6822844 and rs907715), *IL2RA* (2104286, rs11594656 and rs12722495) and *IL2RB* (rs743777) genetic variants were genotyped using TaqMan® allelic discrimination assays.

Results: A statistically significant difference was found for the rs6822844 (*IL2/IL21* region) minor allele frequency in the group of uveitis patients compared with controls ($P_{\text{value}}=0.02$, OR=0.64 CI 95%=0.43-0.94) although the significance was lost after multiple testing correction. Furthermore, no evidence of association with uveitis was detected for the analyzed genetic variants of the *IL2RA* or *IL2RB* loci.

Conclusion: Our results indicate that analyzed *IL2/IL21*, *IL2RA* and *IL2RB* polymorphisms do not seem to play a significant role on the non-anterior uveitis genetic predisposition although further studies are needed in order to clear up the influence of these loci on the non-anterior uveitis susceptibility.

Keywords: Uveitis, *IL2*, *IL21*, *IL2RA*, *IL2RB*, Polymorphisms, Association study, Genetic susceptibility

Background

Uveitis is an intraocular inflammatory disorder mediated by a wide range of causes, including exogenous and endogenous agents. This condition is considered a major source of visual impairment being the fourth cause of blindness worldwide [1,2]. Endogenous uveitis is an inflammatory response mediated by immune system driven for a loss of tolerance against ocular antigens [3].

A shared genetic component among different autoimmune diseases is well established. This fact has suggested that these disorders may be influenced by both disease-specific and common molecular mechanisms [4]. Indeed, the autoimmune uveitis also seems to share common genetic factors with other autoimmune disorders [5]. To date, different studies have been conducted in order to identify the uveitis genetic component [6-9], although results have been inconclusive. It is important to note that the majority of studies on uveitis susceptibility have been focused on anterior uveitis and few studies have been carried out to determine the non-anterior uveitis genetic background.

* Correspondence: mccenit@ipb.csic.es

†Equal contributors

¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN, CSIC, Parque Tecnológico Ciencias de la Salud, Avenida del Conocimiento s/n 18100-Armilla, Granada, Spain

Full list of author information is available at the end of the article

Interleukin 2 (IL-2) was initially identified as an auto-crine product from activated T cells, although later was found that IL-2 plays a crucial role in the maintenance of immune system homeostasis and self-tolerance [10]. The main non-redundant function of this cytokine seems to be the regulation of peripheral tolerance by supporting the survival and function of regulatory T cells. In fact, mice deficient in IL-2, IL-2R α , and IL-2R β exhibit autoimmunity [11,12]. In uveitis condition, IL-2 induces the expansion of Th17 cells, which were found to be elevated in uveitis patients [13]. Moreover, Daclizumab therapy, a monoclonal antibody against alpha subunit of the IL-2 receptor, reduces the active uveitis inflammation [14].

On the other hand, interleukin 21 (IL-21) is a potent immunomodulatory cytokine with pleiotropic effects on both innate and adaptive immune responses. IL-21 is produced mainly by CD4⁺ T cells and promotes the effector CD8⁺ T cells and NK cells function and expansion. In addition, it is also critical for B-cell differentiation into plasma cells and negatively regulates the function of dendritic cells [15]. Recently, it has been suggested that the dendritic cells maturation seems play a role in the pathogenesis of endogenous uveitis [16]. Furthermore, IL-21 seems to be involved in the Behçet's disease (BD) [17] as well as in the Vogt-Koyanagi-Harada (VKH) syndrome pathogenesis [18], both disorders strongly characterized by the presence of uveitis condition, probably by promoting IL-17 secretion.

Different studies with animal models have clearly supported the involvement of IL-21 as well as IL2/IL2R pathway as potential drivers of autoimmunity [19-24]. Additionally, genetic associations between different polymorphisms located within the *IL2/IL21* region as well as within both *IL2RA* and *IL2RB* loci and several autoimmune diseases have also been reported [25-34].

Regarding the *IL2RA* gene, different independent signals on this gene were identified by fine mapping of the region, and their minor alleles were related to inherited lower circulating levels of the soluble IL-2RA protein, [25-27,29]. IL-2RA is expressed constitutively on regulatory T cells, a population of T cells that has been shown to have a potent ability to suppress autoreactive T cells [35].

Taking into account all of the above, we herein aimed to investigate whether the previously most associated polymorphisms with different autoimmune disorders located in *the IL2/IL21*, *IL2RA* and *IL2RB* loci are involved in the genetic predisposition to autoimmune uveitis. For this purpose, we studied three SNPs located within the *IL2/IL21* region (rs907715, located within the *IL21* gene and most associated SNP with SLE in a recent fine mapping, rs2069762 situated within the *IL2* gene and rs6822844 positioned in the *IL2/IL21* inter-genic region), three functional independent Single Nucleotide Polymorphisms (SNPs) related with lower circulating levels

of the soluble IL-2RA (rs11594656, rs2104286 and rs12722495) and one SNP in the *IL2RB* locus (rs743777), all of them previously associated to multiple autoimmune conditions through genome-wide association studies [28,30-34].

Methods

Study population

We included a total of 196 patients with endogenous uveitis, excluding the anterior uveitis forms as well as uveitis associated with systemic immune-mediated diseases except Vogt-Koyanagi-Harada syndrome, and 760 ethnically matched healthy controls, all of them from Caucasian population. Furthermore, uveitis patients were classified depending on the part of eye affected by the inflammatory process in intermediate uveitis (IU), posterior uveitis (PU) or panuveitis (PAN) [36]. Written informed consent and approval of the local ethical committees were obtained and the research followed the tenets of the Declaration of Helsinki. The design of the work was approved by the Ethics Committee of Granada (Spain). The Ethics Committees of the Hospital de León (León), Hospital Universitario Príncipe de Asturias (Alcalá de Henares), Hospital de Cruces (Bilbao), Hospital Clinic (Barcelona), Hospital Clínico San Carlos (Madrid), Hospital Marqués de Valdecilla (Santander), Hospital Universitario La Fe (Valencia), Hospital Clínico San Cecilio (Granada) and Hospital Carlos Haya (Málaga) also approved the study.

Genotyping and SNP selection

Genomic DNA was extracted from peripheral white blood cells following standard procedures. The single-nucleotide polymorphisms (SNPs) were genotyped using pre-designed TaqMan[®] allelic discrimination assays in a 7900HT Real-Time polymerase chain reaction (PCR) System from Applied Biosystems (Foster City, CA, USA).

We carried out the genotyping of the rs2069762, rs6822844 and rs907715 genetic variants, located within the 4q27 (*IL2/IL21*) region, rs11594656, rs2104286 and rs12722495 in the *IL2RA* gene and rs743777 located within the *IL2RB* locus.

Statistical analysis

The Linux software Plink v1.7 (<http://pngu.mgh.harvard.edu/purcell/plink/>) was used to perform 2x2 contingency tables, χ^2 and/or Fisher's exact tests, when appropriate. The genotype, allele and carrier frequencies were compared between patients, subgroup of patients and controls. Odds ratios (OR) and 95% confidence intervals (CI) were obtained according to Woolf's method. Hardy-Weinberg equilibrium (HWE) was tested for all SNPs at significance level=0.01. Since different polymorphisms were analyzed in the current study, *the* Benjamini & Hochberg (1995)

step-up false discovery rate (FDR) control correction for multiple testing was applied to the *P*-values. *P*-values after FDR correction lower than 0.05 were considered as statistically significant.

Furthermore, the effect of the analyzed genetic variants located within the 4q27 as well as within the *IL2RA* gene was analyzed either in isolation or by allelic combination analysis in order to cover a higher variability of these chromosome regions.

The overall statistical power of our study according to Power Calculator for Genetic Studies 2006 software (<http://www.sph.umich.edu/csg/abecasis/CaTS/>), is shown in online Additional file 1: Table S1.

Results

Table 1 describes the main clinical and demographic characteristic of uveitis patients included in the current study and Table 2 shows the genotypic and allelic frequencies in cases and controls. The intraocular inflammation seen in patients included intermediate uveitis (18.4%), posterior uveitis (55.1%), and panuveitis (23.5%).

No statistically significant deviation from Hardy-Weinberg equilibrium ($P \leq 0.01$) was observed for all the studied SNPs in the control set and the frequencies of the analyzed SNPs were in agreement with the data of the HapMap project. Genotyping success rate was higher than 95% for all analyzed SNPs. In addition, randomly selected samples were genotyped twice to verify the genotyping accuracy and 99% of the genotypes were identical.

In the case/control analysis, we detected a decrease of the minor allele frequency of the rs6822844 (*IL2/IL21* region) in the group of uveitis patients ($P_{\text{value}}=0.02$, OR=0.64 CI 95%=0.43-0.94). Nevertheless, when we applied the FDR correction the significance was lost ($P_{\text{FDR}}=0.17$) (Table 2). Additionally, no statistical significant differences were observed in the genotype, allele and carriers frequencies for the analyzed *IL2RA* and *IL2RB* SNPs between uveitis patients and controls.

Table 1 Clinical and demographic features of uveitis patients and controls

General characteristics	Uveitis patients (n=196)	Controls (n=760)
Male(%)/Female (%)	83 (42.3)/113 (52.1)	254 (33.4)/506 (66.6)
Age (mean ± SD)	46.3 ± 15.48	45.12 ± 12.21
Intermediate Uveitis (%)	36 (18.4)	-
Posterior Uveitis (%)	108 (55.1)	-
Panuveitis (%)	46 (23.5)	-
Bilateral affection (%)	149 (68.7)	-
Vitritis (%)	135 (62.2)	-
Macular edema (%)	89 (41.0)	-
Retinal vasculitis (%)	83 (38.2)	-
Choroidal neovascularization (%)	20 (9.2)	-

When we compared the different subgroups of uveitis patients stratified according to the different main features showed in Table 1 no statistically significant differences were detected for none of the analyzed polymorphisms (data not shown).

On the other hand, the allelic combination analysis of the studied polymorphisms located within the *IL2/IL21* chromosome region as well as within the *IL2RA* gene did not provide additional information (Tables 3 and 4, respectively).

Discussion

Although the etiology of uveitis is not fully understood yet, multiple evidences have strongly suggested that alterations in the immune system may underlie the dysfunction observed in endogenous uveitis [37]. To date, different functional studies have supported that the T-regulatory cells as well as Th17 cells seem to confer protection from and risk to intraocular inflammation, respectively [38]. IL-2 promotes development of regulatory T cells and confers protection from autoimmune disease [10] whereas IL-21 promotes differentiation of Th17 cells and is implicated in the development of several autoimmune diseases [15]. Interestingly, on the one hand IL-2 inhibits the differentiation of Th17 cells, although on the other hand it induces the expansion of Th17 cells once developed that mediate uveitis [13]. Therefore, taking into account all these evidences and the shared genetic component among the different autoimmune diseases, in the present study we aimed to analyze the influence of different polymorphisms located within the *IL2/IL21*, *IL2RA* and *IL2RB* loci, previously associated to multiple autoimmune disorders, on the non-anterior autoimmune uveitis susceptibility.

It is important to note that although we observed a weak association of the rs6822844 *IL2/IL21* polymorphism with uveitis, it did not reach statistical significance after multiple testing correction, probably due to the large number of tests performed and the limited statistical power to detect moderate effects (Additional file 1: Table S1). For this reason, further studies are needed in order to confirm the possible *IL2/IL21* genetic region influence on the non-anterior uveitis genetic background. This polymorphism has been studied in several autoimmune diseases such as celiac disease, type 1 diabetes and rheumatoid arthritis and showed a protective effect in all of them. In this way, our results for the rs6822844 are in agreement with the effect formerly observed for other conditions suggesting a common underlying mechanism [31,32,34]. The rs6822844 polymorphism probably may be acting as genetic marker of another nearby causal polymorphism in tight linkage disequilibrium with it. In addition, after confirmation of the *IL2/IL21* genetic region influence on uveitis genetic

Table 2 Allelic and genotype frequencies of *IL2/IL21*, *IL2RA* and *IL2RB* genetic variants in uveitis patients and healthy controls from Spanish population

SNP	1/2	Subgroup (n)	11	12	22	MAF (%)	Allelic P-value	OR (95% CI)
<i>IL2/IL21</i>								
rs2069762	C/A	Controls (n=760)	61 (8.03)	315 (41.45)	384 (50.53)	437 (28.75)	0.49	1.09 (0.85-1.40)
		Uveitis (n=195)	17 (8.71)	85 (43.60)	93 (47.69)	119 (30.51)		
rs6822844	T/G	Controls (n=760)	15 (1.97)	156 (20.53)	589 (77.50)	186 (12.24)	0.02*	0.64 (0.43-0.94)
		Uveitis (n=196)	2 (1.02)	28 (14.29)	166 (84.69)	32 (8.16)		
rs907715	T/C	Controls (n=760)	81 (10.66)	330(43.42)	349(46.92)	492 (32.37)	0.64	0.94 (0.74-1.20)
		Uveitis (n=196)	26 (13.27)	70 (35.71)	100 (51.02)	122 (31.12)		
<i>IL2RA</i>								
rs12722495	G/A	Controls (n=760)	3 (0.39)	114 (15.00)	643 (84.61)	120 (7.90)	0.73	1.07 (0.72-1.60)
		Uveitis (n=196)	2 (1.02)	29 (14.80)	165 (84.18)	33 (8.42)		
rs2104286	C/T	Controls (n=760)	19 (2.50)	270 (35.53)	471 (61.97)	308 (20.26)	0.95	1.01 (0.77-1.33)
		Uveitis (n=196)	10 (5.10)	60(30.61)	126 (64.29)	80 (20.41)		
rs11594656	T/A	Controls (n=760)	84 (11.05)	346(45.53)	330(43.42)	514 (33.82)	0.10	0.82 (0.64-1.04)
		Uveitis (n=196)	23 (11.79)	69 (35.38)	103 (52.82)	115 (29.49)		
<i>IL2RB</i>								
rs743777	G/A	Controls (n=760)	86(11.32)	349(45.92)	325(42.76)	521 (34.28)	0.39	0.90 (0.71-1.14)
		Uveitis (n=195)	26 (13.40)	72 (37.11)	96 (49.48)	124 (31.96)		

* $P_{FDR-corrected}=0.17$.

SNP; Single Nucleotide Polymorphism.

MAF; Minor Allele Frequency.

OR; Odds Ratio.

predisposition, more studies would be required in order to reveal the causal variant/s responsible and to clear up the influence of this region on the uveitis etiology. Importantly, a better knowledge of the uveitis etiology could allow a successful and more personalized treatment of the disease.

The association of *IL2RA* polymorphisms with autoimmunity is more complex and a given polymorphism may show the opposite effect in different autoimmune disorders [27]. Our results indicate that the analyzed *IL2RA* and *IL2RB* polymorphisms do not seem to play a significant role on the non-anterior uveitis genetic predisposition, similar to what has been reported in other autoimmune diseases such as inflammatory bowel disease and celiac disease. In these diseases underlying mechanisms different to the IL-2-dependent pathway would probably be involved in the perturbed development of regulatory T cells. Recently,

the *IL2RA* rs2104286 polymorphism has been associated with intermediate uveitis [39]. When we evaluated whether the studied genetic variants were involved in the different uveitis forms we did not observe the any association with the different uveitis subphenotypes. Nevertheless, this no evidence of association between the *IL2RA* locus and intermediate uveitis must be taken with caution because, although the statistical power of the overall analysis in the present study is high (Additional file 1: Table S1; 99% at the 5% significant level to identify the previously detected OR equal to 0.52), the statistical power of the stratified analysis for different uveitis forms is limited and, probably, moderate effects are hardly detected.

Conclusions

Therefore, our results suggest that analyzed *IL2/IL21*, *IL2RA* and *IL2RB* polymorphisms do not seem to play a

Table 3 *IL2/IL21* allelic combinations (rs2069762, rs6822844 and rs907715) in uveitis patients and healthy controls from Spanish population

Allelic combination	Uveitis, n (%)	Controls, n (%)	P-value	OR [95% CI]
AGC	142 (39.3)	596 (39.2)	0.95	1.01 (0.79-1.28)
CGC	106 (29.3)	432 (28.4)	0.71	1.05 (0.81-1.36)
AGT	83 (22.9)	301 (19.8)	0.17	1.21 (0.91-1.61)
ATT	28 (7.8)	185 (12.2)	0.02	0.61 (0.39-0.94)

Table 4 *IL2RA* allelic combinations (rs12722495, 2104286 and rs11594656) in uveitis patients and healthy controls from Spanish population

Allelic combination	Uveitis, n (%)	Controls, n (%)	P-value	OR [95% CI]
ATA	195 (50.8)	714 (47.0)	0.21	1.15 (0.92-1.45)
ATT	112 (29.1)	498 (32.6)	0.16	0.84 (0.65-1.08)
ACA	46 (12.0)	186 (12.4)	0.86	0.97 (0.68-1.39)
GCA	29 (7.5)	106 (7.0)	0.71	1.08 (0.69-1.69)

significant role on the non-anterior uveitis genetic predisposition although additional studies are needed to draw firm conclusions about the exact role of the analyzed genes in the susceptibility and clinical spectrum of uveitis.

Additional file

Additional file 1: Table S1. Overall statistical power for each analyzed genetic variant at the 5% significance level.

Competing interest

The authors declare that they have no competing interest.

Authors' contributions

MCC and AM participated in the design of the study, performed the genotyping, analyzed the data, and drafted the manuscript. JM made substantial contribution to the conception and design of the study, acquisition of data, coordination and drafting of the manuscript. MC-C, AF, AA, AM-B, VL, DD-V, RB, JC, DS, JL G-S, ER, MJR, MBG- E, JM M-V, NO-C participated in the design of the study, performed the statistical analysis and interpretation of data. All the authors revised critically the manuscript, gave necessary attention to ensure the integrity of the work presented, and approved the final version.

Acknowledgements

The authors thank Sofia Vargas, Sonia Rodríguez and Gema Robledo (from Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, Spain) for their excellent technical assistance, and all the patients and healthy controls for kindly accepting their essential collaboration. Banco Nacional de ADN (University of Salamanca, Spain) and Biobanco Vasco para la Investigación (Fundación Vasca de Innovación e Investigación Sanitarias, Bizkaia, Spain) are thanked for supplying part of the samples.

Author details

¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN, CSIC, Parque Tecnológico Ciencias de la Salud, Avenida del Conocimiento s/n 18100-Armilla, Granada, Spain. ²Ophthalmology Department, Hospital de León, León, Spain. ³Internal Medicine Department, Hospital de Cruces, Bilbao, Spain. ⁴Ophthalmology Department, Hospital Clínic, Barcelona, Spain. ⁵Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain. ⁶Rheumatology Department, Hospital Marqués de Valdecilla, IFIMAV, Santander, Spain. ⁷Ophthalmology Department, Hospital Marqués de Valdecilla, Santander, Spain. ⁸Ophthalmology Department, Hospital Universitario La Fe, Valencia, Spain. ⁹Ophthalmology Department, Hospital Clínico San Cecilio, Granada, Spain. ¹⁰Internal Medicine Department, Hospital Carlos Haya, Málaga, Spain. ¹¹Ophthalmology Department, Hospital Carlos Haya, Málaga, Spain. ¹²Ophthalmology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain. ¹³Immunology Department, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. ¹⁴Internal Medicine Department, Hospital Clínico San Cecilio, Granada, Spain.

Received: 8 November 2012 Accepted: 8 May 2013

Published: 15 May 2013

References

- Nussenblatt RB: **The natural history of uveitis.** *Int Ophthalmol* 1990, **14**(5-6):303-308.
- Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A: **Causes and frequency of blindness in patients with intraocular inflammatory disease.** *Br J Ophthalmol* 1996, **80**(4):332-336.
- Commodaro AG, Bueno V, Belfort R Jr, Rizzo LV: **Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation.** *Autoimmun Rev* 2011, **10**(4):205-209.
- Cho JH, Gregersen PK: **Genomics and the multifactorial nature of human autoimmune disease.** *N Engl J Med* 2011, **365**(17):1612-1623.
- Mattapallil MJ, Sahin A, Silver PB, Sun SH, Chan CC, Remmers EF, Hejtmancik JF, Caspi RR: **Common genetic determinants of uveitis shared with other autoimmune disorders.** *J Immunol* 2008, **180**(10):6751-6759.
- Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH: **Identification of novel genetic susceptibility loci for Behcet's disease using a genome-wide association study.** *Arthritis Res Ther* 2009, **11**(3):R66.
- Martin TM, Zhang G, Luo J, Jin L, Doyle TM, Rajaska BM, Coffman JE, Smith JR, Becker MD, Mackensen F, et al: **A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease.** *Arthritis Rheum* 2005, **52**(1):269-274.
- LeHoang P, Ozdemir N, Benhamou A, Tabary T, Edelson C, Betuel H, Semiglia R, Cohen JH: **HLA-A29.2 subtype associated with birdshot retinochoroidopathy.** *Am J Ophthalmol* 1992, **113**(1):33-35.
- Oruc S, Duffy BF, Mohanakumar T, Kaplan HJ: **The association of HLA class II with pars planitis.** *Am J Ophthalmol* 2001, **131**(5):657-659.
- Malek TR: **The biology of interleukin-2.** *Annu Rev Immunol* 2008, **26**:453-479.
- Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I: **Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells.** *Eur J Immunol* 1995, **25**(11):3053-3059.
- Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW: **Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment.** *Immunity* 1995, **3**(4):521-530.
- Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE: **TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1.** *Nat Med* 2007, **13**(6):711-718.
- Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, Dahr S, Sran P, Reed GF, Robinson R, et al: **High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.** *J Autoimmun* 2008, **31**(2):91-97.
- Spolski R, Leonard WJ: **Interleukin-21: basic biology and implications for cancer and autoimmunity.** *Annu Rev Immunol* 2008, **26**:57-79.
- Kim TW, Kang JS, Kong JM, Bae S, Yu Y, Chung H, Yu HG: **Maturation profiles of peripheral blood dendritic cells in patients with endogenous uveitis.** *Immunol Lett* 2012, **142**(1-2):14-19.
- Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, Tran TA, Bodaghi B, Musset L, Soumelis V, et al: **Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease.** *J Allergy Clin Immunol* 2011, **128**(3):655-664.
- Li F, Yang P, Liu X, Wang C, Hou S, Kijlstra A: **Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent Vogt-Koyanagi-Harada disease.** *Arch Ophthalmol* 2010, **128**(11):1449-1454.
- Sutherland AP, Van Belle T, Wurster AL, Suto A, Michaud M, Zhang D, Grusby MJ, von Herrath M: **Interleukin-21 is required for the development of type 1 diabetes in NOD mice.** *Diabetes* 2009, **58**(5):1144-1155.
- Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer JB, Morse HC 3rd, Leonard WJ, Roopenian DC: **A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSb-Yaa mice.** *Proc Natl Acad Sci USA* 2009, **106**(5):1518-1523.
- Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K: **IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.** *J Immunol* 2007, **178**(6):3822-3830.
- Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, et al: **Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.** *Arthritis Rheum* 2007, **56**(4):1152-1163.
- Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuura T, Schmits R, Sirmard JJ, Ohashi PS, Griesser H, et al: **Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta.** *Science* 1995, **268**(5216):1472-1476.
- Wang L, Yu CR, Kim HP, Liao W, Telford WG, Egwuagu CE, Leonard WJ: **Key role for IL-21 in experimental autoimmune uveitis.** *Proc Natl Acad Sci USA* 2011, **108**(23):9542-9547.
- Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, et al: **Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.** *Nat Genet* 2007, **39**(9):1074-1082.
- Carr EJ, Clatworthy MR, Lowe CE, Todd JA, Wong A, Vyse TJ, Kamesh L, Watts RA, Lyons PA, Smith KG: **Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis.** *BMC Med Genet* 2009, **10**:22.

27. Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, Severson C, Clark PM, Healy B, Walker N, Aubin C, et al: **IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.** *PLoS Genet* 2009, **5**(1):e1000322.
28. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, et al: **Risk alleles for multiple sclerosis identified by a genome-wide study.** *N Engl J Med* 2007, **357**(9):851–862.
29. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C, et al: **Shared and distinct genetic variants in type 1 diabetes and celiac disease.** *N Engl J Med* 2008, **359**(26):2767–2777.
30. Wellcome Trust Case Control Consortium: **Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.** *Nature* 2007, **447**(7145):661–678.
31. van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, Wapenaar MC, Barnardo MC, Bethel G, Holmes GK, et al: **A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21.** *Nat Genet* 2007, **39**(7):827–829.
32. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, et al: **Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.** *Nat Genet* 2007, **39**(7):857–864.
33. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger CR, et al: **A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.** *PLoS Genet* 2008, **4**(3):e1000041.
34. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, Coenen MJ, Franke B, Franke L, Posthumus MD, van Heel DA, van der Steege G, et al: **Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases.** *Am J Hum Genet* 2007, **81**(6):1284–1288.
35. Buckner JH: **Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.** *Nat Rev Immunol* 2010, **10**(12):849–859.
36. Deschenes J, Murray PI, Rao NA, Nussenblatt RB: **International Uveitis Study Group (IUSG): clinical classification of uveitis.** *Ocul Immunol Inflamm* 2008, **16**(1):1–2.
37. Chen L, Yang P, Zhou H, He H, Ren X, Chi W, Wang L, Kijlstra A: **Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome.** *Invest Ophthalmol Vis Sci* 2008, **49**(8):3475–3482.
38. Keino H, Takeuchi M, Usui Y, Hattori T, Yamakawa N, Kezuka T, Sakai JJ, Usui M: **Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis.** *Br J Ophthalmol* 2007, **91**(1):105–110.
39. Lindner E, Weger M, Steinwender G, Griesbacher A, Posch U, Ulrich S, Wegscheider B, Ardjomand N, El-Shabrawi Y: **IL2RA gene polymorphism rs2104286 A>G seen in multiple sclerosis is associated with intermediate uveitis: possible parallel pathways?** *Invest Ophthalmol Vis Sci* 2011, **52**(11):8295–8299.

doi:10.1186/1471-2350-14-52

Cite this article as: Céni^t et al: Evaluation of the *IL2/IL21*, *IL2RA* and *IL2RB* genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. *BMC Medical Genetics* 2013 **14**:52.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

